Gilead to support generic lenacapavir in low-income nations
Earlier this month, Gilead Sciences announced that it had signed non-exclusive, royalty-free voluntary licensing agreements…
Posted inNews PrEP Prevention Research
Twice-yearly lenacapavir 89% more effective than Truvada
New data from the PURPOSE 2 study shows that twice-yearly lenacapavir is 89% more effective…
Posted inConferences News Research Treatment
HIV viral rebounds following CRISPR gene therapy
EBT-101, a gene-editing therapy utilising CRISPR technology, showed promising safety and tolerability in an initial…
Posted inHealthcare Medicines News Parenting PrEP Prevention Research
Cabotegravir PrEP injection is safe during pregnancy
The safety and tolerability of long-acting injectable cabotegravir (CAB-LA) as HIV pre-exposure prophylaxis (PrEP) for…
Posted inConferences Cure News Treatment
Man “likely cured” of HIV after stem cell transplant
A new case of prolonged HIV remission was reported during the 25th International AIDS Conference…